Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology
JPM | Free Full-Text | Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes
Table 1 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar
Performance of Ki67 (as a continuous variable) to predict Luminal A or... | Download Scientific Diagram
Frontiers | Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis
Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology
Medicina | Free Full-Text | Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice
Cancer du sein luminal et apport des classifications intrinsèques moléculaires : comment identifier les tumeurs luminales A et B en 2015 ? - ScienceDirect
ROC curve to determine the best Ki-67 cut-point to differentiate... | Download Scientific Diagram
PinPointcases - INACTIVE --- Adjuvant systemic treatment of luminal A/B early breast cancer
Identifying the Best Ki67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification - European Medical Journal
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
![PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a33aa443a365c6282bd5449f8899f125cb99c7a9/3-Table3-1.png "PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar")
PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar
Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. - Abstract - Europe PMC
Ki-67-Based Breast Cancer Recurrence Data | Food for Breast Cancer
a ROC curve of Ki67 in the luminal samples (Prosigna®); b Sankey... | Download Scientific Diagram
Expression of ER, PR, Her2, and Ki-67 by immunohistochemical staining... | Download Scientific Diagram
MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation - Modern Pathology
Subtypes of Breast Cancer - Breast Cancer - NCBI Bookshelf
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
Cancers | Free Full-Text | Valproic Acid and Breast Cancer: State of the Art in 2021
การแบ่งประเภททางโมเลกุลของมะเร็งเต้านม (Molecular classification of breast cancer) | Asian Archives of Pathology
MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers | Diagnostic Pathology | Full Text
PRISE EN CHARGE DES CANCERS DU SEIN HORMONODÉPENDANTS
Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens | Virchows Archiv
